Simultaneous Administration of Pure Antiandrogens, a Combination Necessary for the Use of Luteinizing Hormone-Releasing Hormone Agonists in the Treatment of Prostate Cancer

Although castration levels of serum androgens are consistently achieved after 2-3 weeks of treatment with luteinizing hormone-releasing hormone (LHRH) agonists, the administration of these peptides alone in adult men is always accompanied by a transient increase in plasma testosterone and dihydrotes...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS 1984-06, Vol.81 (12), p.3861-3863
Main Authors: Labrie, Fernand, Dupont, Andre, Belanger, Alain, Emond, Jean, Monfette, Gerard
Format: Article
Language:English
Subjects:
Acid Phosphatase - blood
Adenocarcinoma - drug therapy
Agonists
Androgen antagonists
Androgen Antagonists - administration & dosage
Androgens
Buserelin - administration & dosage
Castration
Drug Therapy, Combination
Estrogens
Humans
Imidazoles - administration & dosage
Imidazolidines
Luteinization
Male
Phosphatases
Prostate
Prostate cancer
Prostatic Neoplasms - drug therapy
Testosterone
Testosterone - blood
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although castration levels of serum androgens are consistently achieved after 2-3 weeks of treatment with luteinizing hormone-releasing hormone (LHRH) agonists, the administration of these peptides alone in adult men is always accompanied by a transient increase in plasma testosterone and dihydrotestosterone levels, which lasts for 5-15 days at the beginning of treatment and is accompanied by disease flare-up in some cases, thus seriously limiting the acceptability of this otherwise efficient and well-tolerated treatment. The present data show that the simultaneous administration of a pure antiandrogen neutralizes the influence of the transient increase in serum androgens on prostate cancer, as indicated by the 60% decrease in serum prostatic acid phosphatase observed within 5 days of combined treatment with an LHRH agonist and a pure antiandrogen. The addition of a pure antiandrogen thus makes fully acceptable the use of LHRH agonists as an advantageous substitute for surgical castration and estrogens in the treatment of prostate cancer.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.81.12.3861